Table 4 Treatment details, response, and subsequent course of disease

From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

Patient

Age (years)

Sex

Stage

Number of treated metastases

IL-2 dose (MIU)

Weeks of treatment

Histopathologic response evaluation

Local response

Subsequent course of systemic disease, systemic therapy

Current status

1

38

F

III

3

281

16

Not done

2 CR, 1 NA

VM (4 M)/T+IFN

DE

2

62

F

III

17

397.5

57

Done

17 CR

Stable

AL, DF

3

69

F

III

5

447

53

Done

5 CR

VM (16 M)/IFN

DE

4

61

M

III

4

61

12

Not done

4 PR

VM (3 M)/T+IFN

DE

5

74

M

III

2

99

8

Not done

2 CR

VM (4 M)/T+IFN

AL, DF

6

59

F

III

3

18

2

Not done

3 CR

Stable

AL, DF

7

83

F

III

1

18

4

Not done

1 CR

VM (6 M)

AL

8

65

M

IV

50

79

8

Done

50 CR

VM (2 M)/T+IFN

DE

9

63

M

III

11

287

18

Done

10 CR, 1 NA

VM (5 M)/IFN

AL

10

58

M

III

1

8

5

Done

1 CR

Stable

AL, DF

11

52

F

IV*

3

115

4

Done

3 CR

Further progression/V

DE

12

30

F

III

3

103

7

Not done

3 CR

Further progression/BOLD

DE

13

35

F

IV*

15

119.2

12

Done

15 PR

Further progression/D+IFN

DE

14

68

M

IV

45

91

4

Done

45 CR

Stable

AL, DF

15

60

F

IV*

7

118

20

Not done

4 NA, 3 PD

Further progression/T

AL

16

66

F

III

5

18

2

Not done

5 CR

Stable

AL, DF

17

64

M

III

1

15.5

2

Done

1 CR

Stable

AL, DF

18

51

F

IV*

4

88

8

Not done

1 PR, 3 PD

Further progression/T+IFN

DE

19

64

F

III

2

175

8

Done

1 CR, 1 PD

VM (7 M)/S+HP

AL, DF

20

78

M

III

20

38.5

12

Done

20 CR

VM (2 M)

AL

21

72

F

III

20

10.5

5

Not done

20 CR

Stable

AL, DF

22

19

M

IV*

2

9

1

Not done

2 NA

Further progression/R

DE

23

59

M

IV*

1

54

3

Not done

1 PR

Further progression/T

AL

24

70

F

III

20

67.5

4

Done

20 CR

Stable

AL, LM

  1. Stage: IV*=visceral metastases; IL-2 dose (MIU): cumulative dose expressed in 106 international units; Response: CR=complete response, PR=partial response, NA=not assessable, PD=progression; Subsequent course of systemic disease: VM (4 M)=progression to stage IV with visceral metastasis (4 months after commencement of IL-2 therapy), D=dacarbazine, IFN=interferon-alfa, T=temozolomide, V=vindesine, BOLD=polychemotherapy (BOLD regimen), S=surgery, HP=hyperthermic limb perfusion, R=radio therapy; Current status (July 2000): Al=alive, DF=disease free, LM=local metastatsis, VM=visceral metastasis, DE=dead.